AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9778000 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg propofol intravenously (group 2)
Number of subjects: 250
Study 9778000 — intervention group
Group type: COMPARATOR
Intervention: Saline (groups 1 and 3)
Number of subjects: 250
Study 7873494 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of activated autologous peripheral blood lymphocytes (after cultivation with anti-CD3 antibody and IL-2)
Number of subjects: 101
Study 7873494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 101
Study 7873494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 3208665 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - fathers involved in care with early discharge (24-48 hours after birth)
Number of subjects: 49
Study 3208665 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - traditional hospital postpartum care (5-6 days stay)
Number of subjects: 49
Study 3208665 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Participating Group (NPG) - parents not interested in early discharge study
Number of subjects: 49
Study 29986023 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous heparinized whole blood (AWB)
Number of subjects: 21
Study 29986023 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 21
Study 29743098 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC at 30 l/min and 31 °C
Number of subjects: 40
Study 29743098 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC at 60 l/min and 31 °C
Number of subjects: 40
Study 29743098 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC at 60 l/min and 31 °C in patients with clinical FiO2 ≥ 45%
Number of subjects: 40
Study 29743098 — intervention group
Group type: COMPARATOR
Intervention: HFNC at 30 l/min and 37 °C
Number of subjects: 40
Study 29743098 — intervention group
Group type: COMPARATOR
Intervention: HFNC at 60 l/min and 37 °C
Number of subjects: 40
Study 27515417 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 48
Study 27515417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24587110 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonics instruction
Number of subjects: 22
Study 24587110 — intervention group
Group type: EXPERIMENTAL
Intervention: Other treatment approaches (including reading fluency trainings, phonemic awareness instructions, reading comprehension trainings, auditory trainings, medical treatments, interventions with coloured overlays or lenses, sunflower therapy, motor exercises)
Number of subjects: 22
Study 23114081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin therapy
Number of subjects: 300
Study 23114081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 20950476 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg AMG 108
Number of subjects: 813
Study 20950476 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg AMG 108
Number of subjects: 813
Study 20950476 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg AMG 108
Number of subjects: 813
Study 20950476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study 17623753 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (9 weeks, 5 days/week, 1 hour/day, 75% Vo(2peak))
Number of subjects: 8
Study 17623753 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretraining trials (45% Vo(2peak) and 65% Vo(2peak))
Number of subjects: 8
Study 17623753 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining trials (ABT and RLT at 65% of pretraining and posttraining Vo(2peak), respectively)
Number of subjects: 8
Study 15871319 — intervention group
Group type: EXPERIMENTAL
Intervention: Minipunch grafting (MPG)
Number of subjects: 64
Study 15871319 — intervention group
Group type: COMPARATOR
Intervention: Split-skin grafting (SSG)
Number of subjects: 64
Study 12419297 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 485
Study 12419297 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (control)
Number of subjects: 485
Study 10327777 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention group (n = 52)
Number of subjects: 93
Study 10327777 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 41)
Number of subjects: 93
Study 8961324 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of physical activity (weight lifting)
Number of subjects: 28
Study 1827096 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg twice daily)
Number of subjects: 77
Study 1827096 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin (150 mg twice daily)
Number of subjects: 77
Study 1827096 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 77
Study 1827096 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin
Number of subjects: 77
Study 6752799 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 500
Study 6752799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 6752799 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 60 years or older
Number of subjects: 500
Study 6752799 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger individuals
Number of subjects: 500
Study 30979666 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial health promotion intervention (manual‐based multi‐component health promotion program based on motivational interviewing and cognitive behavioral therapy)
Number of subjects: 689
Study 30979666 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 689
Study 30979666 — intervention group
Group type: EXPERIMENTAL
Intervention: Run-in period before the start of the active intervention
Number of subjects: 689
Study 27496630 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative transfusion strategy (RBC transfusion for hemoglobin < 7.0 g/dL for biventricular repairs or < 9.0 g/dL for palliative procedures plus clinical indication)
Number of subjects: 162
Study 27496630 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (RBC transfusion for hemoglobin < 9.5 g/dL for biventricular repairs or < 12 g/dL for palliative procedures regardless of clinical indication)
Number of subjects: 162
Study 27496630 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative transfusion strategy
Number of subjects: 162
Study 26561623 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2.4 g/d) for 4 weeks
Number of subjects: 43
Study 26561623 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2.4 g/d) for 4 weeks + aspirin (300 mg/d) during the last 7 days
Number of subjects: 43
Study 26561623 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy matched subjects)
Number of subjects: 43
Study 23751381 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (n = 35)
Number of subjects: 72
Study 23751381 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (n = 37)
Number of subjects: 72
Study 21216507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of methylcobalamin and 5 mg of folic acid once daily for 24 months
Number of subjects: 140
Study 21216507 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 24 months
Number of subjects: 140
Study 19168870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 813
Study 17526862 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF+ group (ATG, CyA, and G-CSF)
Number of subjects: 101
Study 17526862 — intervention group
Group type: COMPARATOR
Intervention: G-CSF- group (ATG and CyA)
Number of subjects: 101
Study 17526862 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF+ group
Number of subjects: 101
Study 17526862 — intervention group
Group type: COMPARATOR
Intervention: G-CSF- group
Number of subjects: 101
Study 15446640 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor balance training on a balance board, wearing ski boots, for 20 min. every second day in the afternoon
Number of subjects: 30
Study 15446640 — intervention group
Group type: COMPARATOR
Intervention: Ski lessons only for two weeks, 2 to 4 hours daily
Number of subjects: 30
Study 11404668 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-body resistance training (TP)
Number of subjects: 68
Study 11404668 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body resistance training (UP)
Number of subjects: 68
Study 11404668 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-body resistance training (TH)
Number of subjects: 68
Study 11404668 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body resistance training (UH)
Number of subjects: 68
Study 11404668 — intervention group
Group type: EXPERIMENTAL
Intervention: Field training (FLD)
Number of subjects: 68
Study 11404668 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AER)
Number of subjects: 68
Study 9536157 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplements (15 mg beta‐carotene, 75 mg vitamin E, and 650 mg vitamin C) once a day for three months
Number of subjects: 26
Study 9536157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 26
Study 7625474 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day of haloperidol
Number of subjects: 24
Study 7625474 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day of haloperidol
Number of subjects: 24
Study 7625474 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day of haloperidol
Number of subjects: 24
Study 2186655 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine 10 mg/kg
Number of subjects: 40
Study 2186655 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 0.1 mg/kg
Number of subjects: 40
Study 371540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 2581
Study 371540 — intervention group
Group type: COMPARATOR
Intervention: Cyclacillin
Number of subjects: 2581
Study 31754300 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 41
Study 31754300 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 41
Study 27112775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT)
Number of subjects: 281
Study 27112775 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 281
Study 26372487 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week intensive fluconazole treatment for CrAg-positive patients
Number of subjects: 72
Study 26372487 — intervention group
Group type: COMPARATOR
Intervention: No treatment (CrAg-negative patients)
Number of subjects: 72
Study 23831139 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to relational aggression
Number of subjects: 150
Study 23831139 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to physical aggression
Number of subjects: 150
Study 23831139 — intervention group
Group type: COMPARATOR
Intervention: Exposure to no aggression (control group)
Number of subjects: 150
Study 20393824 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer education video
Number of subjects: 144
Study 20393824 — intervention group
Group type: COMPARATOR
Intervention: Control group (another program in American Sign Language)
Number of subjects: 144
Study 19229431 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 997
Study 19229431 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises
Number of subjects: 997
Study 19229431 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises + Positive expiratory pressure
Number of subjects: 997
Study 19229431 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure + Inspiratory resistance
Number of subjects: 997
Study 19229431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure breathing
Number of subjects: 997
Study 19229431 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Number of subjects: 997
Study 19229431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure
Number of subjects: 997
Study 16875796 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief patient decision aid (pDA)
Number of subjects: 990
Study 16875796 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaire alone)
Number of subjects: 990
Study 14669315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for 12 months
Number of subjects: 131
Study 14669315 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment-naïve)
Number of subjects: 131
Study 11074989 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiocclusive, heated dressing applied to 15 Stage III and IV pressure ulcers for 4.5 hours, Monday through Friday, for 4 consecutive weeks.
Number of subjects: 20
Study 11074989 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard wound care plus heated dressing.
Number of subjects: 20
Study 11074989 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (control group).
Number of subjects: 20
Study 8842833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 31
Study 8842833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1495849 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ribosomal vaccine D53
Number of subjects: 17
Study 1495849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1495849 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral ribosomal vaccine D53
Number of subjects: 17
Study 6716521 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-gauge Angiocath and 8 Fr pulmonary artery introducer catheter with large-bore intravenous tubing (5.0 mm I.D.)
Number of subjects: 0
Study 6716521 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous tubing (3.2 mm I.D.)
Number of subjects: 0
Study 31450964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experiences (ACEs)
Number of subjects: 12229
Study 31450964 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEs
Number of subjects: 12229
Study 28683845 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐Phenylcaine Zest
Number of subjects: 86
Study 28683845 — intervention group
Group type: COMPARATOR
Intervention: Co‐Phenylcaine Forte
Number of subjects: 86
Study 26306785 — intervention group
Group type: EXPERIMENTAL
Intervention: edus2
Number of subjects: 33
Study 26306785 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 33
Study 24615728 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard breakfast
Number of subjects: 11
Study 24615728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions
Number of subjects: 11
Study 24615728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional protein-rich drink
Number of subjects: 11
Study 24615728 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard breakfast and nutritional protein-rich drink
Number of subjects: 11
Study 24615728 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 11
Study 23226426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy + Cetuximab or Panitumumab
Number of subjects: 1270
Study 23226426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy + Cetuximab
Number of subjects: 1270
Study 23226426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy + Anti-EGFR drugs
Number of subjects: 1270
Study 23226426 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin-based chemotherapy
Number of subjects: 1270
Study 19962799 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants exposed to caraway flavour via mother's milk (n=20)
Number of subjects: 48
Study 19962799 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants not exposed to caraway flavour (non-exposed group, n=20)
Number of subjects: 48
Study 19962799 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants whose mothers consumed caraway-flavoured food (n=8)
Number of subjects: 48
Study 17432692 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingjin Runfei Decoction (QRD) combined with hormone and antibiotic
Number of subjects: 104
Study 17432692 — intervention group
Group type: COMPARATOR
Intervention: Hormone and antibiotic
Number of subjects: 104
Study 17539738 — intervention group
Group type: EXPERIMENTAL
Intervention: Total volumetric BMD (vBMD)
Number of subjects: 36
Study 17539738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness (geometry)
Number of subjects: 36
Study 17539738 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular number (microstructure)
Number of subjects: 36
Study 17539738 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial rigidity (strength)
Number of subjects: 36
Study 17539738 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor-of-risk (fall load/microFE failure load)
Number of subjects: 36
Study 15610365 — intervention group
Group type: EXPERIMENTAL
Intervention: Active omega-3 supplemented group (daily tuna fish oil supplement and omega-3-rich margarines and cooking oils)
Number of subjects: 376
Study 15610365 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo supplement with polyunsaturated margarines and cooking oils)
Number of subjects: 376
Study 15610365 — intervention group
Group type: EXPERIMENTAL
Intervention: Active omega-3 supplemented group
Number of subjects: 376
Study 10845823 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysate calcium concentration (HdCa; 1.75 mmol/L)
Number of subjects: 19
Study 10845823 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysate calcium concentration (LdCa; 1.25 mmol/L)
Number of subjects: 19
Study 10845823 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from HdCa to LdCa treatment
Number of subjects: 19
Study 10845823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LdCa and HdCa treatment groups
Number of subjects: 19
Study 9354201 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy (40 mg once daily, amoxycillin 1 g b.d. for 2 weeks, metronidazole 400 mg t.d.s. for the first week)
Number of subjects: 183
Study 9354201 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole dual therapy (40 mg once daily, amoxycillin 1 g b.d. for 2 weeks, placebo during the first week)
Number of subjects: 183
Study 9354201 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients treated analysis for omeprazole triple therapy
Number of subjects: 183
Study 9354201 — intervention group
Group type: COMPARATOR
Intervention: All patients treated analysis for omeprazole dual therapy
Number of subjects: 183
Study 9354201 — intervention group
Group type: COMPARATOR
Intervention: Follow-up of H. pylori-negative patients
Number of subjects: 183
Study 9354201 — intervention group
Group type: COMPARATOR
Intervention: Consultations, investigations, and prescriptions relating to upper gastrointestinal symptoms
Number of subjects: 183
Study 9354201 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 183
Study 8415473 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (M)
Number of subjects: 83
Study 3545686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 to 20 mg per day)
Number of subjects: 7324
Study 3545686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol alone or in combination with a diuretic
Number of subjects: 7324
Study 3545686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 7324
Study 30017404 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with systematic and targeted biopsy using the Artemis fusion targeting system
Number of subjects: 273
Study 30017404 — intervention group
Group type: COMPARATOR
Intervention: 12-core systematic biopsy
Number of subjects: 273
Study 30017404 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biopsy alone (MRI arm)
Number of subjects: 273
Study 30017404 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsy (MRI arm)
Number of subjects: 273
Study 30017404 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biopsy (MRI arm)
Number of subjects: 273
Study 29031743 — intervention group
Group type: EXPERIMENTAL
Intervention: JZP-110
Number of subjects: 43
Study 29031743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 26215435 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing pioglitazone
Number of subjects: 77
Study 26215435 — intervention group
Group type: COMPARATOR
Intervention: Discontinuing pioglitazone
Number of subjects: 77
Study 24413697 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-study caffeine administration
Number of subjects: 0
Study 22803404 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe vesicles
Number of subjects: 40
Study 22803404 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF beta1 levels in nasal polyps (1-3 weeks group and 6-8 weeks group)
Number of subjects: 40
Study 22803404 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF levels in nasal polyps (6-8 weeks group)
Number of subjects: 40
Study 19448528 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pills (OCPs)
Number of subjects: 599
Study 19448528 — intervention group
Group type: EXPERIMENTAL
Intervention: Depomedroxyprogesterone Acetate (DMPA)
Number of subjects: 599
Study 19448528 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine Device (IUD)
Number of subjects: 599
Study 18036290 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol combined with low dose fentanyl (Group PF)
Number of subjects: 32
Study 18036290 — intervention group
Group type: COMPARATOR
Intervention: Midazolam combined with low dose fentanyl (Group MF)
Number of subjects: 32
Study 15465742 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 12
Study 15465742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11370993 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) applied to the right or left frontal cortex at 0.5 Hz, 130% of motor threshold, 60 stimuli
Number of subjects: 18